The prognostic significance of COX-2 and survivin expression in ovarian cancer

Aihara, 2003, Touch imprint cytology and immunohistochemistry for the assessment of sentinel lymph nodes in patients with breast cancer, Eur. J. Surg. Oncol., 29, 845, 10.1016/j.ejso.2003.09.005

Aihara, 2004, Comparison of frozen section and touch imprint cytology for evaluation of sentinel lymph node metastasis in breast cancer, Ann. Surg. Oncol., 11, 747, 10.1245/ASO.2004.01.014

Ali-Fehmi, 2003, The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma, Cancer, 98, 1423, 10.1002/cncr.11650

Ambrosini, 1997, A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma, Nat. Med., 3, 917, 10.1038/nm0897-917

Bantis, 2004, Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value, Cytopathology, 15, 25, 10.1046/j.0956-5507.2003.00090.x

Barnes, 2005, Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent, Gynecol. Oncol., 98, 376, 10.1016/j.ygyno.2005.05.022

Brinton, 2005, Ovulation induction and cancer risk, Fertil. Steril., 83, 261, 10.1016/j.fertnstert.2004.09.016

Chen, 1994, The role of cytokines in the production of prostacyclin and thromboxane in human mononuclear cells, Immunol. Invest., 23, 269, 10.3109/08820139409066823

Cohen, 2003, Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis, Mod. Pathol., 16, 574, 10.1097/01.MP.0000073868.31297.B0

Cramer, 1998, Over the counter analgesics and risk of ovarian cancer, Lancet, 351, 104, 10.1016/S0140-6736(97)08064-1

Creager, 2004, Intraoperative imprint cytologic evaluation of sentinel lymph nodes for lobular carcinoma of the breast, Ann. Surg., 239, 61, 10.1097/01.sla.0000103072.34708.e3

Cserni, 2003, Effect of increasing the surface sampled by imprint cytology on the intraoperative assessment of axillary sentinel lymph nodes in breast cancer patients, Am. Surg., 69, 419, 10.1177/000313480306900512

Daponte, 1999, p53 as a prognostic factor for stage III serous adenocarcinoma of the ovary, Anticancer Res., 19, 2387

Denkert, 2002, Expression of cyclooxygenase-2 is an independent prognostic factor in human ovarian carcinoma, Am. J. Pathol., 160, 893, 10.1016/S0002-9440(10)64912-7

Dore, 1998, Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas, J. Histochem. Cytochem., 46, 77, 10.1177/002215549804600110

DuBois, 1994, Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester, J. Clin. Invest., 93, 493, 10.1172/JCI116998

Dutta, 2005, Neoadjuvant chemotherapy for epithelial ovarian cancer—role of apoptosis, Cancer Chemother. Pharmacol., 56, 427, 10.1007/s00280-004-0993-9

Erkinheimo, 2004, Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of Her-2/neu and poor outcome in serous ovarian carcinoma, Clin. Cancer Res., 10, 538, 10.1158/1078-0432.CCR-0132-03

Ferrandina, 2005, Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters, Br. J. Cancer, 92, 271, 10.1038/sj.bjc.6602332

Ferrandina, 2002, Cyclooxygenase-2 (COX-2), epidermal growth-factor receptor (EGFR) and Her-2/neu expression in ovarian cancer, Gynecol. Oncol., 85, 305, 10.1006/gyno.2002.6620

2003, Annual report on the results of treatment in gynecological cancer, Int. J. Gynaecol. Obstet., 83, 1

Flens, 1990, The contribution of immunocytochemistry in diagnostic cytology. Comparison and evaluation with immunohistology, Cancer, 65, 2704, 10.1002/1097-0142(19900615)65:12<2704::AID-CNCR2820651218>3.0.CO;2-F

Gallo, 2001, Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis, Neoplasia, 3, 53, 10.1038/sj.neo.7900127

Greene, 1991, DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report, Cancer Res., 51, 4084

Harris, 2005, Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review), Oncol. Rep., 13, 559

Hsu, 1981, Use of avidin–biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures, J. Histochem. Cytochem., 29, 577, 10.1177/29.4.6166661

Huang, 1998, Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production, Cancer Res., 58, 1208

Ito, 2000, Survivin promotes cell proliferation in human hepatocellular carcinoma, Hepatology, 31, 1080, 10.1053/he.2000.6496

Kawasaki, 1998, Inhibition of apoptosis by survivin predicts shorter survival rates of colorectal cancer, Cancer Res., 58, 5071

Khalifeh, 2004, Expression of Cox-2, CD34, Bcl-2 and p53 and survival in patients with primary peritoneal serous carcinoma and primary serous carcinoma, Int. J. Gynecol. Pathol., 23, 162, 10.1097/00004347-200404000-00011

Khuri, 2001, Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer, Clin. Cancer Res., 7, 861

Klevesath, 2005, Touch imprint cytology of core needle biopsy specimens: a useful method for immediate reporting of symptomatic breast lesions, Eur. J. Surg. Oncol., 31, 490, 10.1016/j.ejso.2005.01.004

Klimp, 2001, Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages, Cancer Res., 61, 7305

Koss, 2006, Recognizing and classifying cells, 119

Krysan, 2004, Cyclooxygenase-2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer, Cancer Res., 64, 6359, 10.1158/0008-5472.CAN-04-1681

Krysan, 2004, COX-2 dependent stabilization of survivin in non-small cell lung cancer, FASEB J., 18, 206, 10.1096/fj.03-0369fje

Li, 2005, Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2 and Bcl-2 in borderline ovarian tumors, Arch. Gynecol. Obstet., 272, 48, 10.1007/s00404-004-0708-9

Lin, 2005, Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells, Biochem. Pharmacol., 70, 658, 10.1016/j.bcp.2005.05.028

Ma, 2005, Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides, Oncol. Rep., 14, 275

Mano, 1999, Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer, Eur. J. Cancer, 35, 1214, 10.1016/S0959-8049(99)00124-0

Matsumoto, 2001, Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms, Int. J. Mol. Med., 8, 31

Monzo, 1999, A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers, J. Clin. Oncol., 17, 2100, 10.1200/JCO.1999.17.7.2100

Munkarah, 2005, COX-2: a protein with an active role in gynecological cancers, Curr. Opin. Obstet. Gynecol., 17, 49, 10.1097/00001703-200502000-00009

Munkarah, 2003, Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor NS398 in epithelial ovarian cancer cells, Gynecol. Oncol., 88, 429, 10.1016/S0090-8258(03)00084-2

O’Banion, 1992, cDNA cloning and functional activity of a glycocorticoid-regulated inflammatory cyclooxygenase, Proc. Natl. Acad. Sci. USA, 89, 4888, 10.1073/pnas.89.11.4888

Ozzello, 1991, An immunohistochemical evaluation of progesterone receptor in frozen sections, paraffin sections, and cytologic imprints of breast carcinomas, Cancer, 67, 455, 10.1002/1097-0142(19910115)67:2<455::AID-CNCR2820670223>3.0.CO;2-M

Pennati, 2005, Potential use of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down regulation, Mol. Cancer Ther., 4, 1328, 10.1158/1535-7163.MCT-05-0022

Qui, 2005, Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death, Int. J. Oncol., 27, 1441

Raspollini, 2004, Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome, Gynecol. Oncol., 92, 806, 10.1016/j.ygyno.2003.12.023

Raspollini, 2005, Increased cyclooxygenase-2 (COX-2) expression and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with high and low survival, Int. J. Gynecol. Cancer, 15, 255, 10.1111/j.1525-1438.2005.15212.x

Richardon, 1985, Common epithelial cancer of the ovary (2), N. Engl. J. Med., 312, 474, 10.1056/NEJM198502213120804

Rosenberg, 2000, A case–control study of analgesic use and ovarian cancer, Cancer Epidemiol. Biomarker Prev., 9, 933

Sakamoto, 2004, Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferators activated-receptor gamma in epithelial ovarian tumors, Br. J. Cancer, 91, 633, 10.1038/sj.bjc.6602009

Sakuma, 1999, Cyclooxygenase(COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer, J. Gastoenterol., 34, 189, 10.1007/s005350050242

Sarela, 2000, Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma, Gut, 46, 645, 10.1136/gut.46.5.645

Sasaki, 2002, Cytologic diagnosis of estrogen and progesterone receptors in breast imprints, Acta Cytol., 46, 1056, 10.1159/000327107

Seo, 2004, Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer, Gynecol. Oncol., 92, 927, 10.1016/j.ygyno.2003.11.055

Sheng, 1998, Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells, Cancer Res., 58, 362

Shigemasa, 2003, Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas, Int. J. Oncol., 22, 99

Shirahama, 2001, Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder, Cancer, 92, 188, 10.1002/1097-0142(20010701)92:1<188::AID-CNCR1308>3.0.CO;2-W

Subbaramaiah, 1999, Inhibition of cyclooxygenase-2 gene expression by p53, J. Biol. Chem., 274, 10911, 10.1074/jbc.274.16.10911

Sui, 2002, Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors, Int. J. Oncol., 21, 315

Surowiak, 2006, Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers, Cancer Lett., 235, 272, 10.1016/j.canlet.2005.04.035

Symowicz, 2005, Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells, Cancer Res., 65, 2234, 10.1158/0008.5472.CAN-04-2781

Tanaka, 2000, Expression of survivin and its relationship to loss of apoptosis in breast carcinomas, Clin. Cancer Res., 6, 127

Takai, 2002, Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma, Int. J. Mol. Med., 10, 211

Tiniakos, 1996, C-erb B-2 and p53 expression in breast cancer fine needle aspirates, Cytopathology, 7, 178, 10.1046/j.1365-2303.1996.39482394.x

Tringler, 2004, Immunohistochemical localization of survivin in serous tumors of the ovary, Appl. Immunohistochem. Mol. Morphol., 12, 40, 10.1097/00129039-200403000-00008

Tsujii, 1995, Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2, Cell, 83, 493, 10.1016/0092-8674(95)90127-2

Tsujii, 1998, Cyclooxygenase regulates angiogenesis induced by colon cancer cells, Cell, 93, 705, 10.1016/S0092-8674(00)81433-6

Vane, 1994, Towards a better aspirin, Nature, 567, 215, 10.1038/367215a0

Wang, 2005, Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells, Cancer Biol. Ther., 4, 716, 10.4161/cbt.4.7.1782

Werner, 2000, Effect of formalin fixation and processing on immunohistochemistry, Am. J. Surg. Pathol., 24, 1016, 10.1097/00000478-200007000-00014

Yoshida, 2001, Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas, Int. J. Oncol., 19, 537

Zaffaroni, 2002, Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer, Cell Mol. Life Sci., 59, 1406, 10.1007/s00018-002-8518-3